Prot #BB2121-MM-007: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Project: Research project

Project Details

StatusFinished
Effective start/end date8/6/21 → 8/6/24

Funding

  • DrugDev Inc. (Prot #BB2121-MM-007 // Prot #BB2121-MM-007)
  • Celgene Corporation (Prot #BB2121-MM-007 // Prot #BB2121-MM-007)